1 / 58

Joint ACC/CMGS MRCPath Pt 2 Study Day, Nov 2007 Future Impact of Complex Disorders &

Joint ACC/CMGS MRCPath Pt 2 Study Day, Nov 2007 Future Impact of Complex Disorders & Pharmacogenetics on Genetic Testing Dr Ian M Frayling Consultant in Genetic Pathology Institute of Medical Genetics University Hospital of Wales Cardiff ian.frayling@cardiffandvale.wales.nhs.uk.

inga
Download Presentation

Joint ACC/CMGS MRCPath Pt 2 Study Day, Nov 2007 Future Impact of Complex Disorders &

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Joint ACC/CMGS MRCPath Pt 2 Study Day, Nov 2007 Future Impact of Complex Disorders & Pharmacogenetics on Genetic Testing Dr Ian M Frayling Consultant in Genetic Pathology Institute of Medical GeneticsUniversity Hospital of Wales Cardiff ian.frayling@cardiffandvale.wales.nhs.uk

  2. On Developments • Developments in place when one is born are accepted as the natural order of things

  3. On Developments • Developments in place when one is born are accepted as the natural order of things • Developments in the first third of one’s existence are accepted as new and exciting and something one could make a career in

  4. On Developments • Developments in place when one is born are accepted as the natural order of things • Developments in the first third of one’s existence are accepted as new and exciting and something one could make a career in • Developments in the middle third of one’s existence are thought of as against the natural order of things

  5. On Developments • Developments in place when one is born are accepted as the natural order of things • Developments in the first third of one’s existence are accepted as new and exciting and something one could make a career in • Developments in the middle third of one’s existence are thought of as against the natural order of things • \,=Q-X%&!>@;##B86 z`zzz……

  6. On Developments • Developments in place when one is born are accepted as the natural order of things • Developments in the first third of one’s existence are accepted as new and exciting and something one could make a career in • Developments in the middle third of one’s existence are thought of as against the natural order of things • \,=Q-X%&!>@;##B86 z`zzz…… The Hitch-hiker’s Guide to the Galaxy, Douglas Adams

  7. Some fundamentals • Phenotype = genotype + environment • Environment of 1 gene includes 2 x 29,999 others • Evolution by natural selection (change) occurs as a consequence of a struggle for survival (competition) where there are differences (variation) within the system that can be selected (fitness) • The Internet & search engines

  8. Complex Disorders

  9. Complex Disorders • Are there any simple ones? • Down’s, CF, FraX, HD, cancer, thrombophilia … • What’s Mendelian? • Can clinical variety be predicted? • Is it worth predicting? Should it be?

  10. Complex Disorders • Are there any simple ones? • Why variety/complexity? • Metabolic polymorphism • Modifiers • genetic • environmental

  11. Complex Disorders • Are there any simple ones? • Why variety/complexity? • Unless you can test for most of the cause of the variety it is probably not worth testing for any of it • [CF and alleles and risk reduction] • BRCA and SNPs

  12. Pharmacogenetics • Treatment: pharmacology and therapeutics • Genetic variation that has a bearing on this • Promises to individualise therapy, savings in time, money, adverse events, better therapeutic effect • What genetic tests do we currently do that have an impact on treatment?

  13. Pharmacogenetics • Treatment: pharmacology and therapeutics • Genetic variation that has a bearing on this • Promises to individualise therapy, savings in time, money, adverse events, better therapeutic effect • What genetic tests do we currently do that have an impact on treatment?

  14. Pharmacogenetics • What genetic tests do we currently do that have an impact on treatment?

  15. Pharmacogenetics • What genetic tests do we currently do that have an impact on treatment? • Haemophilia

  16. Pharmacogenetics • What genetic tests do we currently do that have an impact on treatment? • Haemophilia • Leukaemia

  17. Pharmacogenetics

  18. Pharmacogenetics • Treatment: pharmacology and therapeutics • Genetic variation that has a bearing on this • Absorbtion/assimilation • Metabolic • Activation > Action (Receptor binding) • Inactivation • Excretion • SIDE EFFECTS

  19. Pharmacogenetics • Where’s the variation? • Absorbtion/assimilation • Metabolic • Activation > Action (Receptor binding) • Inactivation • Excretion

  20. Pharmacogenetics • Metabolic • Activation • Phase 1 and Phase 2 metabolism • Prodrugs • P450, GST, NAT • > Action (Receptor binding): Receptors vary • Inactivation • P450, CYP2D6 etc etc • Excretion

  21. Gene-Environment Combinations in CRCa • Adenoma risk and Aspirin • CYP2C9 activates, UGT1A6 deactivates: Bigler J, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk Cancer Res 2001;61:3566-9

  22. Gene-Environment Combinations in CRCa • Adenoma risk and Aspirin • CYP2C9 activates, UGT1A6 deactivates: Bigler J, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk Cancer Res 2001;61:3566-9

  23. Gene-Environment Combinations in CRCa • Adenoma risk and Aspirin • CYP2C9 activates, UGT1A6 deactivates: Bigler J, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk Cancer Res 2001;61:3566-9

  24. Pharmacogenetics • Familial Hypercholesterolaemia • LDLR, APOB, PCSK9 • “Acquired” hypercholesterolaemia • PCSK9 variants are associated with: • Increased risk of CHD • & need for more expensive treatment in FH • Decreased risk of CHD • & better response to treatment in FH • GP > [chol] > Hi > genetic testing > report to GP on drug suitability, and cascade testing if FH

  25. Pharmacogenetics • SIDE EFFECTS • This is what really scares the drug companies, and the NHS: -£££ • Testing for adverse event susceptibility will probably be the priority – avoiding nasty dangerous expensive events • Testing for drug preference is likely “second phase”: +£££

  26. Pharmacogenetics • Who’s going to do this? • Timeliness: m.1555A>G • £61k Rx, £18k pa education • BIG business – 100,000s of tests • Reports to Drs, pharmacists, nurses … • Pathway: GP, generic Rx, blood test, report to pharmacist, specific Rx issued • How much interpretation is needed? • How will it be provided?

  27. Tumour testing in Sporadic CRCa • MSI in 20% of sporadic colon* cancers • Theoretical reasons to expect differences in response to chemotherapy MSI+/- • Old studies showed response to BCNU in 20% colon cancers • Large prospective studies in progress

  28. Tumour testing in Sporadic CRCa • MSI in 20% of sporadic colon* cancers • Theoretical reasons to expect differences in response to chemotherapy MSI+/- • Old studies showed response to BCNU in 20% colon cancers • Large prospective studies in progress • 2007: MRC K-ras & topo2 IHC • What will happen when a £50 test predicts response to £15k of chemotherapy? • And 15,000 colon cancers pa need testing …

  29. Tumour testing in Sporadic CRCa • MSI in 20% of sporadic colon* cancers • Theoretical reasons to expect differences in response to chemotherapy MSI+/- • Old studies showed response to BCNU in 20% colon cancers • Large prospective studies in progress • 2007: MRC K-ras & topo2 IHC • What will happen when a £50 test predicts response to £15k of chemotherapy? • And 15,000 colon cancers pa need testing … • Within 7 calendar days!

  30. Future impact of complex disorders and pharmacogenetics • Exiting • Challenging • Potentially great benefit

  31. Pharmacogenetics etc • Slides not in the lecture but alluded to …

  32. Metabolism of drugs (and other foreign compounds) • Complex system - “DME”s • Evolved to cope with natural organic compounds • Phase I enzymes • Cytochrome P450: CYP • Phase II enzymes • N-acetyl transferases: NAT1, NAT2 • Glutathione S-transferases: GSTM1, GSTP1, GSTT1 • Sulphotransferase: SULT • Others • Microsomal epoxide hydrolase: mEH • Myeloperoxidase: MPO • Great individual gene / gene family variation, even more combinations Houlston RS & Tomlinson IPM. Polymorphisms and colorectal tumor risk. Gastroenterology 2001;121:282-301.

  33. N H 2 N N C H 3 IQ N H N O H H N O S O 3 C H PhIP 3 N N H H N O C H 2 3 N N O H R C O S O 2 2 H R C O H 2 7 B[a]P B [ a ] P ( O H ) B [ a ] P ( O H ) 2 4 HETEROCYCLIC AMINES Carcinogen Activation REACTIVE PRODUCTS OF METABOLISM MPO CYP SULT CYP NH+ NAT1 NAT2 CYP C+ AROMATIC AMINES 4-ABP POLYCYCLIC AROMATIC HYDROCARBONS SULT CYP 7,12 DMBA Epoxide mEH CYP. MPO CYP SULT [C+] mEH Adapted from: Williams JA Carcinogenesis 2001;22:209-214.

  34. Metabolism • Cytochrome P450: CYP family • Colorectal cancer: • CYP1A1 I462V: OR 7.9 [CI 1.4 - 44] • CYP1A1 6325T/C: no association • Sivaraman L et al. CYP1A1 genetic polymorphisms and in situ colorectal cancer. Cancer Res 1994;54:3692-5 • Houlston R & Tomlinson I. Polymorphisms and colorectal tumor risk. Gastroenterology 2001;121:282-301

  35. Metabolism • N-acetyl transferase: NAT2 • 50-60% Caucasians are slow acetylators • Colorectal cancer: • 15 population studies • 4 phenotype - increased risk if rapid acetylators • 11 genotype - no association • overall no association • Houlston R & Tomlinson I. Gastroenterology 2001;121:282-301 • 1 study in HNPCC • MSH2/MLH1 gene carriers more likely penetrant if slow acetylators (P <0.03) Heinimann K et al. Cancer Res 1999;59:3038-40 • Breast cancer: • no association, but not expressed in mammary epithelium!

  36. Metabolism • Glutathione S-transferase: GST family • Colorectal cancer: • GSTM1 null • increased risk in 5 studies, only significant in 2 • 1 study: proximal tumour risk, not otherwise confirmed • no relationship with adenoma risk • GSTT1 null • increased risk in 2 studies • nil or decreased risk in 5 studies • GSTP1 105I/V and 114A/V • no relationship • Houlston R & Tomlinson I. Gastroenterology 2001;121:282-301

  37. Metabolism • Sulph / fotransferase: SULT family • SULT1A1 R213H: Arg ~65% • Arg allele 10~300x less active at mutagen activation • Glatt H et al. Sulphotransferases: genetics and role in toxicology. Toxicol Lett 2000;112-113:341-348. • Needs exploring

  38. Metabolism • Microsomal epoxide hydrolase: mEPHX • Colorectal cancer: • One study • Y113H • Y homozygosity significantly increased risk • 139H/R • no association • problem with population stratification • Harrison DJ et al. Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer 1999;79:168-171.

  39. Metabolism • Myeloperoxidase: MPO • ex-neutrophils • Lung cancer: • c.-463G/A = loss of SP1 transcription binding site • G:A 3:1 • 4 studies: • 182 cases, 459 controls: OR 0.30 (P = 0.04; cauc.) • 157 cases, 244 controls: OR 0.61 (ns; african) • 323 cases, 437 controls: OR 0.50 • 196 cases, 255 controls: OR 0.47 (P = 0.004) • 93 cases, 121 controls: OR 0.52 (P = 0.02) • Williams JA. Single nucleotide polymorphisms, metabolic activation and environmental carcinogenesis: why molecular epidemiologists should think about enzyme expression. Carcinogenesis 2001;22:209-214.

  40. Overall mutation rate is a function of: Environment Pro-carcinogens Pro-carcinogens metabolism excretion Carcinogens Micro- Environment DNA DNA Repair Cell turnover Micronutrients Antioxidants ...

  41. Individualisation in CRCa • NSAIDs • Consistent association between NSAID use and reduced risk of CRCa: RR 0.63 • Aspirin is subject to metabolic activation and deactivation

  42. Individualisation in CRCa • Adenoma risk and Aspirin • CYP2C9 activates, UGT1A6 deactivates: Bigler J, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk Cancer Res 2001;61:3566-9

  43. Individualisation in CRCa • Adenoma risk and Aspirin • CYP2C9 activates, UGT1A6 deactivates: Bigler J, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk Cancer Res 2001;61:3566-9

  44. Individualisation in CRCa • Adenoma risk and Aspirin • CYP2C9 activates, UGT1A6 deactivates: Bigler J, et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk Cancer Res 2001;61:3566-9

  45. DNA Repair

  46. DNA Repair • necessary because DNA is subject to damage • dsDNA for more than one reason • very old (conserved) function • only one DNA toolkit • bacterial mutator loci • keeps mutation rate low, but not zero

  47. DNA Damage, Repair & Consequences DNA repair Cell cycle arrest Mutagenic survival ? DNA Damage Toxic death Apototic death

  48. DNA Damage, Repair & Consequences DNA repair Cell cycle arrest Mutagenic survival ? DNA Damage Toxic death Apototic death All a function of amount of damage, repair, and cell turnover

  49. DNA Damage • most mutations due to misincorporation of dNTPs, due to damaged bases • very rarely ‘spontaneous’ • A, C, G & T exist as tautomers, but equilibria very ‘one-sided’ ...

  50. Why A, C, G & T?

More Related